ENA0000GenomicsSurgery, St Jude Children's Research Hospitalhttps://www.ebi.ac.uk/ena/browser/view/PRJNA384369Homo sapiensThrough a small scale metabolic-modulator screening, we have identified dimethyl fumarate (DMF), a FDA approved drug for multiple sclerosis, which suppresses neuroblastoma cell growth in vitro and in vivo. Mechanistically, DMF suppresses neuroblastoma cell growth through inducing ROS and subsequently suppressing MYCN expression. Overall design: Biological duplicate samples were treated with 100uM of DMF for 6 and 12 hours.ENAxN-myc1, Neuroblastoma (Schwannian Stroma-Poor), hypersensitivity, hypersensitive, Drives, neuroblastoma, Neuroblastomas, Neuroblastoma, Nmyc, malignant, Central neuroblastoma, ODED, neural Crest tumor, mycna, mycnb, neuroblastoma (Schwannian Stroma-poor), Nmyc1, N-myc, Nmuc1, neuroblastoma (morphologic abnormality), Sympathicoblastoma, Nmyc-1, neuroblastoma NOS (morphologic abnormality), [M]Neuroblastoma NOS (morphologic abnormality), allergic reaction, MODED, mycn, MCF3, (Neuroblastoma NOS) or (sympathicoblastoma), XN-myc, sensitive, NMYC, [M]Neuroblastoma NOS, c-nmyc, hypersensitivity reaction disease, (neuroblastoma NOS) or (sympathicoblastoma), NOS, NB, hypersensitivity reaction, NB - Neuroblastoma, neuroblastoma (Schwannian Stroma-Poor), bHLHe37, ROS, c-ros-1., nmyc, sensitivity, XNmychuman being, human., man0.00.00.00.00.00falseHomo sapiensMYCN drives glutaminolysis in neuroblastoma and confers sensitivity to ROS augmenting agents2022-05-122018-04-19PRJNA384369GSE98241294451629606